MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.
Sources
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Inovație în medicina de laborator: MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Latest News
23:14
The mayor of Iași announced the cessation of street lighting at night due to the energy crisis. The measure will save approximately 10 MWh per night.
22:41
A SpaceX rocket out of control will crash on the Moon, forming a 27-meter crater.
22:01
Greece is facing new wildfires. A suburb of Athens has already been evacuated.
21:26
Traian Băsescu: Bolojan needs to rebuild the coalition with PSD for the good of the country
21:05
The Romanian Army has been mobilized to protect the operation of the Cernavodă Nuclear Power Plant, carrying out hydrographic measurements on the Danube.
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
